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Accepted 27 January 2017Introduction: Polysubstance use disorder is prevalent in treatment-seeking patients with substance use disorder
(SUD), with a higher risk of developing comorbid psychiatric symptoms, more pervasive deficits in cognitive
functions, and inferior treatment results. The present study investigates if individualswith polysubstance use dis-
order who achieve at least one year of abstinence show greater improvements in satisfaction with life, executive
functions, and psychological distress, compared to relapsers and controls. The prospective recovery from
polysubstance use disorder assessedwith broad output indicators remains understudied. A better understanding
of the pattern of recovery of the chosen output indicators could shed light on the recovery process for this group
of patients.
Material and methods: We investigated changes in satisfaction with life, executive functions and psychological
distress over a period of 12 months in patients who remained abstinent and in those who relapsed. Subjects
with polysubstance use disorder (N= 115) were recruited from outpatient and residential treatment facilities;
healthy controls (N = 34) were recruited by posters exhibited at social welfare and GP offices. Executive func-
tions were assessed by the Behaviour Rating Inventory of Executive Function-Adult self-report version (BRIEF-
A), psychological distress by the Symptom Checklist-90-R (SCL-90-R), and satisfaction with life by the Satisfac-
tionWith Life Scale (SWLS). Substance use was assessed by self-reports on the Alcohol Use Disorders Identifica-
tion Test (AUDIT) and the Drug Use Disorders Identification Test (DUDIT). Participants were categorized as
“relapsers” if they had AUDIT score ≥8, or DUDIT score ≥2 for women and ≥6 for men.
Results: Results indicated that the abstinent group had the greatest improvement on all the indicators compared
with relapsers and controls. Participants who successfully quit substance use for one year showed improved sat-
isfaction with life, executive functions, and psychological distress compared to participants who relapsed and
controls.
Conclusions:Our study provides support for the view that there is a clinically and statistically significant recovery
of satisfactionwith life, executive functions, and psychological distress for SUD patients following one-year of ab-
stinence. This knowledge highlights the importance of time and continued abstinence.
Our findings suggest that a gradual and careful step-up of learning requirement should be adopted, and SUD
treatment should initially focus on stabilizing the patient and achieving abstinence, while interventions for co-
morbid problems and more cognitively demanding treatment components are more likely to succeed later in
the treatment sequence.
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patients seeking treatment for substance use, and polysubstance use is
also associated with several challenges (Andrade, Carroll, & Petry,
2013). Comparedwith single-drug users, polydrug users have an earlier
onset of drug use and a higher rate of dropout (King & Canada, 2004;
Preti, Prunas, Ravera, & Madeddu, 2011), and they report higher levels
of general psychological distress (Andreas, Lauritzen, & Nordfjærn,
2015; Quek et al., 2013; White et al., 2013). This group reports more
symptoms of anxiety and depression (Booth et al., 2010; G. W. Smith,
Farrell, Bunting, Houston, & Shevlin, 2011), which is clinically relevant
because psychiatric comorbidity increases risk of relapse (Flynn &
Brown, 2008). Furthermore, polysubstance use disorder is associated
with pervasive deficits in cognitive functions, and significant impair-
ments have been reported on neuropsychological tests of working
memory, inhibition, cognitive flexibility, self-regulation, and decision-
making (Moreno-López et al., 2012). Cognitive impairments and psy-
chological distress thus place users with polysubstance use disorder at
preeminent risk of impaired recovery and more treatment dropout
(Preti et al., 2011) Consequently, treatment approaches for
polysubstance use disorder are less effective compared with treatments
for use of single substances (Connor, Gullo, White, & Kelly, 2014;
Williamson, Darke, Ross, & Teesson, 2006).
A number of studies have found a co-occurrence between mental
distress and dose- related polydrug use, and also a reduction of mental
distress among abstinent patients (Andreas et al., 2015). However, ef-
forts that focus on a broad spectrum of output indicators are needed
to shed light on the recovery process for this important and highly vul-
nerable subgroup of SUD patients. Polydrug users constitute a high risk
group comparedwith other SUD patients, withmore distinct depressive
and suicidal symptomatology at treatment admission (Riehman, Iguchi,
& Anglin, 2002), and also more social anxiety (Bakken, Landheim, &
Vaglum, 2005). Studies have shown that impaired psychiatric and cog-
nitive functions greatly diminish satisfaction with life (Burgess et al.,
2000). Satisfaction with life is also reduced among SUD patients, al-
though it has not been thoroughly investigated in patients with
polysubstance use disorder. (Donovan, Mattson, Cisler, Longabaugh, &
Zweben, 2005; K. Smith & Larson, 2003). As satisfaction with life is de-
scribed as a core motivator for and predictor of successful treatment, it
should be included as a key outcome indicatorwhen evaluating the suc-
cess of SUD treatment (De Maeyer, Vanderplasschen, & Broekaert,
2010).
Previous treatment studies of impaired executive functions in SUD
patients have several limitations. They have primarily dealt with the
acute and subacute effects of chronic alcohol and drug use
(Fernandez-Serrano, Perez-Garcia, & Verdejo-Garcia, 2011; Vik,
Cellucci, Jarchow, & Hedt, 2004; Yucel, Lubman, Solowij, & Brewer,
2007), and studies of long-term recovery do not always require a 14-
day drug-free period prior to baseline testing (Fernandez-Serrano et
al., 2011). Other studies have small sample sizes, oftenwith a focus onpa-
tients with one primary addiction (Badiani, Belin, Epstein, Calu, &
Shaham, 2011; Buelow & Suhr, 2009; Stavro, Pelletier, & Potvin, 2013).
In addition,many studies have used cross-sectional designs andare there-
fore unable to track changes in individual patients over time (van Holst &
Schilt, 2011). There is also considerable variability in the follow-up rates,
ranging from 40% to 98% (Cottler, Compton, Ben-Abdallah, Horne, &
Claverie, 1996; Desmond, Maddux, Johnson, & Confer, 1995; Stinchfield,
Niforopulos, & Feder, 1994), and some studies have not included a
follow-up procedure for a control group (Schulte et al., 2014).
We havenot been able tofindother studies that have focused on sat-
isfactionwith life, executive functions, and psychological distress during
the course of recovery for people with polysubstance use disorder, even
though a consideration of all these variables could prove important to
understand the course of recovery for these patients. The present
study features a prospective design and a control group, and was usedto address the following question: Will individuals with polysubstance
use disorder who achieve at least one year of abstinence show greater
improvements in satisfactionwith life, executive functions, and psycho-
logical distress, compared to relapsers and controls?
2. Material and methods
2.1. Participants
One hundred fifty SUD patients were recruited from 10 outpatient
and residential treatment facilitieswithin the Stavanger University Hos-
pital catchment area (Norway) betweenMarch 2012 andMay2013.We
employed broad inclusion criteria focusing on polysubstance use disor-
der because polysubstance use disorder is common in a clinical setting
(Badiani et al., 2011; Stavro et al., 2013). The main inclusion criteria at
baseline were: (a) evidence of SUD polysubstance use, operationalized
as the use of more than one drug on a single occasion, or a history of
abusing multiple drugs; (b) enrolled in a new treatment sequence by
the substance use treatment service; and (c) at least 16 years of age.
The control group (N= 38) was a convenience sample recruited by
posters exhibited at social welfare and GP offices. Controls and SUD pa-
tients were compensatedwith NOK 400 (~$US 50) for the baseline test-
ing. During the one-year follow-up period, 13 SUD patients and four in
the control group withdrew or dropped out of the study. The final
group included 115 SUD patients and 34 controls. This study was
reviewed and approved by the Regional Ethical Committee (REK
2011/1877) and conducted according to its guidelines and those of the
Helsinki Declaration (1975). Signed informed consent was obtained
from all the participants.
2.2. Procedures
The study is part of a prospective cohort study of a sample of SUD
patients in the Stavanger University Hospital catchment area. To mini-
mize contamination from drug withdrawal and acute neurotoxic effects
from psychoactive substances, baseline assessment was performed after
two weeks of abstinence (Miller, 1985) by experienced and trained
staff. Information on substance use was assessed using the Alcohol Use
Disorders Identification Test (AUDIT) (Bohn, Babor, & Kranzler, 1995)
and the Drug Use Disorders Identification Test (DUDIT) (Voluse et al.,
2012). At the one-year follow up, patients were defined as relapsing to
a significant level of use if they had an AUDIT score ≥8 or DUDIT score
≥2 for women and ≥6 for men (Bohn et al., 1995; Voluse et al., 2012).
2.3. Satisfaction with life
Satisfaction with life was assessed baseline and one year later with
the Satisfaction With Life Scale (SWLS) (Diener, Emmons, Larsen, &
Griffin, 1985). This is a self-report questionnaire including five items
measuring the global life satisfaction experienced by the respondent.
The SWLS has demonstrated good psychometric characteristics (Pavot
& Diener, 2008). The five items are all set in a positive direction, and
the total SWLS score (range = 5–35) was included in the present
study. A score of 20 represents a neutral point on the scale; scores be-
tween 5 and 9 indicate that the respondent is very dissatisfied with
life, while scores ranging between 31 and 35 indicate that the respon-
dent is very satisfied with life (Pavot & Diener, 2008). In this study
two patients did not complete the SWLS at the 1-year follow up, yield-
ing a response rate was 98.2% for patients and 100% for controls.
2.4. Executive functions
This study assessed executive functions by asking the participants to
complete the Behaviour Rating Inventory of Executive Function- Adult
version (BRIEF-A) (Gioia, Isquith, Guy, Kenworthy, & Baron, 2000;
Roth, Isquith, & Gioia, 2005) at baseline and one year later. The BRIEF-
Table 1
Baseline demographic and clinical variables for participants, grouped according to drug
use status after one year.




Age 28.7 (7.5) 27.1 (8.1) 30.9 (12.9)
Male gender, n (%) 35 (68.6%) 42 (65.6%) 15 (55.9%)
Years of education 11.9 (1.8) 11.6 (1.7) 14.2 (3.1)
AUDIT score at baseline 12.3 (9.8) 15.2 (10.5) 5.4 (3.8)
DUDIT score at baseline 36.6 (9.6) 35.3 (8.7) 0.3 (1.2)
WASI IQ 100.7 (11.5) 95.8 (12.1) 105.5 (13.6)
AUDIT=Alcohol Use Disorder Identification Test; DUDIT=Drug Use Disorder Identifica-
tion Test; WASI = Wechsler Abbreviated Scale of Intelligence. All data are means (SD),
unless otherwise indicated.
Fig. 1. Satisfaction with life “Satisfaction with life baseline and one year later measured
with the Satisfaction With Life Scale (SWLS). Mean value for the control group, the
participants that remained abstinent and the participants that relapsed to drug use.
Error bars: 95% Confidence interval.”
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Roth et al., 2005), and to be associated with substance use status as
well as several social adjustment indicators in patients with a history
of polysubstance use disorder (Hagen et al., 2016). The BRIEF-A includes
three composite scores including sets of subscales. A Behavioural Regu-
lation Index (BRI-index) is calculated from the Inhibit, Shift, Self-Moni-
tor and Emotional Control subscales. The BRIEF-A Metacognition Index
(MI) is calculated from the Initiate, Plan/Organize, Working Memory,
Organization of Materials, and Task Monitor subscales. In this study
one patient and one control did not complete the BRIEF-A at the 1-
year follow up, yielding a response rate was 99.1% for patients and
97.1% for controls. Validity scales of the BRIEF-A were examined, using
the cut-off scores proposed by the original authors (Gioia et al., 2000).
Invalid response style led to exclusion of one control and nine SUD par-
ticipants at baseline, and three controls and five SUD participants at the
one-year follow up. The final sample included the 30 controls and 101
SUD patients with valid BRIEF-A protocols.
The Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler,
1999) was used to estimate intellectual function (IQ) by including two
tests of verbal crystallized abilities (Vocabulary and Similarities) and
two tests of nonverbal fluid-visual abilities (Block Design andMatrices)
(Canivez, Konold, Collins, & Wilson, 2009).
2.5. Psychological distress
Psychological distress was measured at baseline and one year later
using the Symptom Checklist-90-R (SCL-90-R) (Derrogatis, 1994). This
is a 90-item self-report symptom inventory that yields measures of nine
symptomdomains of psychological distress: (1) Somatization; (2) Obses-
sive compulsion; (3) Interpersonal sensitivity; (4) Depression; (5) Anxi-
ety; (6) Hostility; (7) Phobic anxiety; (8) Paranoid ideation, and (9)
Psychoticism. This study includes the nine subscales and the summary
score; Global Severity Index (GSI) (Derrogatis, 1994). In this study three
patients did not complete the SCL-90-R at the 1-year follow-up, yielding
a response rate was 97.4% for patients and 100% for controls.
2.6. Statistical analyses
Data were analyzed using IBM SPSS v22 for Mac. Statistical signifi-
cance was interpreted at p b 0.05 (two-tailed). Group differences were
analyzed using t-tests, Mann–Whitney U tests, and Pearson's chi
square-tests when appropriate. Levene's test was used to select the ap-
propriate p-values based onwhether the assumption of equal variances
within groups was met. Histograms, Q–Q plots, Kolmogorov–Smirnov
tests, and Shapiro–Wilk tests were used to investigate normality.
The research question was analyzed using mixed between–within
subjects' ANOVA to compare changes in abstainers, relapsers and con-
trols from the baseline to the one-year follow -up. Variables where the
three groups have similar patterns of change from baseline to one
year will not have a statistically significant interaction effect (the null
hypothesis). Variables where one group has a different pattern of change
from the other two groups are expected to show an interaction. To deter-
mine the cause of interaction effects, Wilcoxon signed rank tests were
used to evaluate median change from baseline to one year within each
group. Effect sizes were calculated as Cohen's r for nonparametric data,
where 0.3 is considered a medium and 0.5 is considered a large effect
(Cohen, 1988). Main effects were not interpreted in the presence of a
statistically significant interaction (Bordens & Abbott, 2002).
3. Results
3.1. Group characteristics
At baseline, patients and controls were similar according to age, but
controls were more often female (chi square = 5.8, p = 0.016), had
higher level of education (Z = 4.1, p b 0.001), and higher IQ score atbaseline (t = 3.2, p b 0.001). Clinical and demographic variables after
one year for patients who remained abstinent (N = 51), relapsers
(N = 64), and controls (N = 34) are summarized in Table 1. Although
there were no differences in baseline demographic variables between
the two SUD groups, the abstinent group obtained a higher score on
WASI IQ (t=2.2, p=0.030). Baseline levels of substance abuse, asmea-
sured bymean AUDIT/DUDIT score, did not differ between the two SUD
groups.
3.2. Satisfaction with Life Scale (SWLS)
Analysis of SWLS showed a significant main effect of group
[F(2144) = 59.8, p b 0.001] and time [F(1144) = 16.9, p b 0.001], and
a significant group × time interaction [F(2144) = 9.84, p b 0.001]. Fol-
low-up analyses showed that the interaction could be attributed to
the significant improvement in the abstinent group (Z = −4.86,
P b 0.001), with a medium to large effect size (r = 0.49). The relapse
and control group did not have statistically significant improvement.
See Fig. 1 and Table 2.
3.3. Executive functions in everyday life (BRIEF-A)
Analysis of the BRIEF-A Global Executive Composite (GEC) showed a
significant main effect of group [F(2125) = 20.4, p b 0.001] and time
Table 2
Self-reported executive functioning, psychological distress and life quality during the 1 year follow up period.
Abstinent group (N = 51) Relapse group (N = 64) Control group (N = 32)
Baseline 1 year Z valuea Baseline 1 year Z valuea Baseline 1 year Z valuea
SWLS sum 15.7 (6.1) 21.1 (6.6) –4.9⁎⁎ 14.9 (5.8) 16.6 (6.1) –1.9 27.4 (4.8) 26.9 (5.5) –0.4
BRIEF-A GEC 64.8 (11.8) 55.0 (12.3) –4.5⁎⁎ 66.4 (9.4) 64.7 (10.2) –1.5 52.3 (10.4) 48.7 (12.7) –2.0⁎
BRIEF-A BRI 63.3 (11.2) 53.5 (11.5) –4.4⁎⁎ 64.0 (12.5) 63.3 (10.2) –0.2 51.0 (9.3) 49.3 (11.0) –1.9
BRIEF-A MI 64.0 (11.6) 55.3 (11.9) –4.5⁎⁎ 63.7 (13.1) 63.9 (11.0) –1.5 53.1 (10.7) 50.1 (10.3) –1.1
SCL-90-R GSI 1.0 (0.7) 0.5 (0.6) –4.5⁎⁎ 1.3 (0.6) 1.1 (0.6) –2.4⁎ 0.4 (0.4) 0.4 (0.5) –0.1
Somatization 0.87 (0.8) 0.43 (0.5) –3.8⁎⁎ 1.10 (0.7) 1.09 (0.8) –0.1 0.41 (0.5) 0.49 (0.5) –1.4
Obsessive compulsive 1.44 (0.8) 0.85 (0.8) –4.9⁎⁎ 1.61 (0.7) 1.43 (0.8) –2.1⁎ 0.58 (0.6) 0.52 (0.6) –1.0
Interpersonal sensitivity 1.22 (0.9) 0.59 (0.8) –4.5⁎⁎ 1.30 (0.7) 1.01 (0.7) –3.2⁎⁎ 0.38 (0.4) 0.41 (0.6) –0.6
Depression 1.23 (0.8) 0.66 (0.7) –4.5⁎⁎ 1.49 (0.7) 1.26 (0.8) –0.4⁎ 0.43 (0.5) 0.45 (0.5) –0.8
Anxiety 1.13 (0.9) 0.47 (0.6) –5.2⁎⁎ 1.42 (0.8) 1.26 (0.8) –2.1⁎ 0.32 (0.4) 0.35 (0.5) –0.7
Hostility 0.64 (0.8) 0.30 (0.5) –3.7⁎⁎ 0.91 (0.8) 0.81 (0.9) –1.2 0.20 (0.2) 0.23 (0.5) –0.8
Phobic anxiety 0.79 (0.9) 0.35 (0.6) –3.9⁎⁎ 1.10 (0.9) 0.84 (0.8) –2.1⁎ 0.17 (0.4) 0.19 (0.4) –0.2
Paranoid ideation 0.97 (0.9) 0.48 (0.7) –3.9⁎⁎ 1.21 (0.9) 1.10 (0.9) –1.2 0.35 (0.4) 0.35 (0.6) –0.7
Psychotisism 0.63 (0.7) 0.24 (0.4) –4.7⁎⁎ 0.71 (0.6) 0.52 (0.5) –2.55⁎ 0.14 (0.3) 0.24 (0.5) –1.8
All data are means (SD), unless otherwise indicated.
BRIEF-A GEC = Behaviour Rating Inventory of Executive Function–Adult Version Global Executive Composite; SCL-90-R GSI = Symptom Checklist-90-Revised Global Severity Index;
SWLS = Satisfaction With Life Scale; AG= Abstinent group; RG = Relapse group; CG= Control group.
⁎ P b 0.05.
⁎⁎ P b 0.001.
a Results of Wilcoxon signed rank test. This measures improvement in median score in this group from baseline until one year later.
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teraction [F(2125)= 4.4, p=0.015]. The interaction is mainly attribut-
ed to the improvement in the abstinent group (Z = −4.52, P b 0.001),
with a medium to large effect size (r = 0.45), but some of the interac-
tion-effect could also be carried by an improvement in the control
group (Z=−2.04, P b 0.05), but this effect was small (r=0.2). The re-
lapse group did not show a statistically significant improvement. See
Fig. 2 and Table 2.
The BRIEF-A Behavioral Regulation Index (BRI) showed a significant
group × time interaction [F(2126) = 4.9, p = 0.009]. The interaction
could be attributed to the improvement in the abstinent group
(Z = −4.5, P b 0.001), with a large effect size (r = 0.6). Relapsers and
controls did not show a statistically significant improvement from base-
line to one year. BRIEF-AMetacognition Index (MI) showed a significant
group × time interaction [F(2126) = 4.0, p = 0.020]. The interactionFig. 2. Executive functions “Executive functions at baseline and one year later measured
with the Global Executive Composite (GEC) from the Behavior Rating Inventory of
Executive Function – Adult Version (BRIEF-A). Mean value for the control group, the
participants that remained abstinent and the participants that relapsed to drug use.
Error bars: 95% Confidence interval.”could be attributed to the improvement in the abstainers (Z = −4.5,
P b 0.001), with a large effect size (r = 0.6). Relapsers and controls
did not have statistically significant improvement. See Table 2.
3.4. Symptom Checklist-90-R (SCL-90-R)
Analysis of psychological distress as measured by SCL-90-R Global
Severity Index (GSI) showed a significant main effect of group
[F(2143)= 24.7, p b 0.001] and time [F(1143)= 23.8, p b 0.001], in ad-
dition to a significant group × time interaction [F(2143) = 11.0,
p b 0.001]. The interaction is mainly attributed to the improvement in
the abstinent group (Z=−4.50, P b 0.001), with a medium to large ef-
fect size (r=0.45), but some of the interaction-effect could also be car-
ried by an improvement in the relapse group (Z=−2.44, P b 0.05), but
this effect was small (r = 0.2). The control group did not have statisti-
cally significant improvement. See Fig. 3 and Table 2.
All nine SCL-90 subscales showed significant interactions at p b 0.05.
The abstinent group improved from baseline to one-year on all nine
subscales (p b 0.001). The relapse group improved on the subscales; Ob-
sessive compulsive, interpersonal sensitivity, depression, anxiety, pho-
bic anxiety and psychoticism at a p b 0.05 level, but showed no
significant change on the subscales somatization, hostility, paranoid
ideation. The control group had no change from baseline to one year
on any of the SCL-90 subscales. See Table 2.
3.5. 3.4 abstinent vs. controls at baseline and one year
At baseline the abstinent group had significantly worse SWLS score
(Z = −6.6, p b 0.001), BREIF-A GEC score (Z = −4.6, p b 0.001) and
SCL-90-R GSI score (Z = −5.0, p b 0.001) compared to the control
group. Comparing the scores at the 1-year follow-up between the absti-
nent and control group demonstrated a significant difference in scores
on SWLS score (Z = −3.91, P b 0.001) and BREIF-A GEC score
(Z=−2.21, P b 0.05), but no evident difference between these groups
on SCL-90-R GSI score. Although the abstinent group performed slightly
worse compared to the control group (see Fig. 3), this differencewas in-
significant and indicates a normalization of psychological distress fol-
lowing one year of abstinence.
3.6. Summary
Significant interactionswith group and timewere shown for all out-
come variables, with the abstainers showing the highest improvement
Fig. 3. Psychological distress “Psychological distress at baseline and one year later
measured with the Global Severity Index (GSI) from the Symptom Checklist 90 –
Revised (SCL-90-R). Mean value for the control group, the participants that remained
abstinent and the participants that relapsed to drug use. Error bars: 95% Confidence
interval.”
85E. Hagen et al. / Journal of Substance Abuse Treatment 76 (2017) 81–87on all variables (see Table 2). Overall, participants that successfully quit
substance use for one year show improved satisfaction with life, execu-
tive functions and psychological distress compared to participants that
relapse and controls.
4. Discussion
This study compared the change frombaseline to follow-up one year
later on self-reported satisfactionwith life, executive functions and psy-
chological distress. The participants were patients with polysubstance
use disorder who remained abstinent during the course of one year, pa-
tients who relapsed to substance use, and healthy controls. The absti-
nent group showed a significant improvement in perceived life
quality, executive functions, and psychological distress compared with
the relapsers and controls.
4.1. Improvement of satisfaction with life, executive functions and, psycho-
logical distress.
Executive functions (EF) improved in the group of abstinent patients
between baseline and one-year, but this was not the case with the pa-
tients that relapsed. Improvement of EF is very promising, considering
that maladaptive, impulse-driven behaviour is strongly associated
with a substance using lifestyle (Crews & Boettiger, 2009). Impulsivity
and impaired EF have been associated with almost all stages of the
SUD life cycle (Stevens et al., 2014): with increased probability of initi-
ating use, more aggressive escalation of use, failure to reduce consump-
tion and higher numbers of relapses after treatment (Jentsch, 2009;
Robbins, Gillan, Smith, de Wit, & Ersche, 2012; Winstanley, Olausson,
Taylor, & Jentsch, 2010). Notably, despite the improvement in EF in
the abstainers, they still had somewhat impaired function compared
with controls, which indicates that they still had some degree of vulner-
ability related to impaired EF, even after a year of abstinence.
Psychological distress decreased in the abstinent group. At the one-
year follow up, the disparity between the abstinent group and the con-
trols almost disappeared, suggesting a normalization of psychological
distress following one year of abstinence. Together with the differencesbetween the relapsers and abstinent patients on almost all SCL-90 sub-
scales, these results offer a promising view regarding initial recovery
from psychological distress in SUD patients. This finding is in line with
previous research that have found a reduction of psychological distress
among patients who stopped using multiple drugs (Andreas et al.,
2015), however it should be emphasized that the present study focused
on a broader spectrum of output indicators than previously reported.
There was a significant difference in perceived satisfaction with life
as measured by SWLS between the abstinent and relapse groups after
one year. The importance of this finding is substantiated by previous
studies showing an association between satisfactionwith life and subse-
quent symptoms in recovery, where satisfaction with life increases
through early recovery to stable abstinence (Laudet, Morgen, & White,
2006). Furthermore, a longer period of sobriety is shown to predict
higher levels of satisfaction with life one year later, and satisfaction
with life at the end of SUD treatment predicts commitment to sobriety
(Laudet et al., 2006).
Themultimodal improvement of satisfaction with life and executive
functionswith a decrease of psychological distress following one year of
abstinence is compelling. Most therapeutic interventions for SUD, in-
cluding, cognitive behavioral therapy, motivational interviewing, and
12-step programs, are verbally based interventions requiring extensive
cognitive processing to facilitate cognitive, motivational, and behavioral
change (Roehrich & Goldman, 1993). For instance, a common feature of
most treatment initiatives involves learning the harmful effects of vari-
ous drugs, as well as teaching of programme rules and overarching
treatment philosophy (Grohman & Fals-Stewart, 2003), thus
representing a distinct learning requirement at the onset of therapy.
Our findings suggest that a gradual and careful step-up of learning re-
quirements should be adopted, and emphasize that SUD treatment
should initially focus on stabilizing the patient and achieving absti-
nence, while interventions for co-morbid problems andmore cognitive-
ly demanding treatment components are more likely to succeed later in
the treatment sequence, as cognitive functioning improves. Moreover,
these results raise possibility that interventions specifically designed
to improve cognitive function, such as memory training (Bickel, Yi,
Landes, Hill, & Baxter, 2011), might facilitate somewhat more rapid re-
covery of cognitive function in this population.
4.2. Strengths and limitations
Many studies in this field have used cross-sectional designs (van
Holst & Schilt, 2011), and thus cannot track changes over time. We
have used a prospective design for the patient and control groups to en-
able control of training effects by repeated testing and reports on the
same questionnaires (Schulte et al., 2014). The mean IQ score of the
control group (104) was within the normal range for the population.
However, there was a significant difference in years of education, gen-
der distribution and work experience between the patient groups and
the controls (Table 1). These disparities are anticipated when compar-
ing a healthy control group and a clinical sample of patients with
polysubstance use disorder with a vast number of risk factors. With re-
gard to education, all Norwegian citizens have compulsory education
from five to 16 years old. It was difficult to recruit age-matched partici-
pants with fewer than 10 years of educationwho did not use drugs. The
skewed gender distribution, with the SUD group being 67% male and
the control group 55.9%male, may be explained by a factual gender dif-
ference in the prevalence of SUD between men and women; males are
more likely to suffer from lifetime and 12-month use and dependence
on drugs (Warner, Kessler, Hughes, Anthony, & Nelson, 1995). There
was no significant age difference between patients and controls,
which was a strength of the study as age is known to significantly im-
pact neurocognitive functions.
To ensure a diverse picture of the dimensions underlying recovery,
we broadened the scope of interest to satisfaction with life, executive
functions and psychological distress. By testing participants after
86 E. Hagen et al. / Journal of Substance Abuse Treatment 76 (2017) 81–8714 days of detoxification, we aimed to exclude the possible subacute ef-
fects of the drug use (Fernandez-Serrano et al., 2011).
However, the present study has a number of limitations. First, it did
not incorporate a randomized design. Relapsers and abstainers self- se-
lected into their groups based on self-reports, and baseline or time-
varying variables that were not assessed may have influenced our out-
come variables. Thus, we cannot conclude that the differences in these
outcomes observed at 12 months were caused only by changes in sub-
stance use status. Furthermore, in this study we only addressed a fol-
low-up period of 12 months with only one follow- up wave, and the
control group was relatively small. It is possible that a larger control
group would have shown statistically significant improvements on EF.
It is however, unlikely that a large control groupwould change the over-
all impression that participants achieving one year of abstinence show
greater improvements compared to the other groups.
Finally, we were not able to determine the patterns of polydrug use
in our sample; that is, whether different substances were used concur-
rently, or before or after another drug. This information would be bene-
ficial to understand better the issues of polydrug use.
5. Conclusions
To date, few studies have investigated the natural progression of re-
covery in terms of this particular combination of outcome indicators in
patients with polysubstance use disorder. Our study provides support
for the view that there is a clinically significant recovery in satisfaction
with life, executive functions and psychological distress for
polysubstance using SUD patients following one-year of abstinence.
This improvement from admission to one-year, suggests that a gradual
progression of treatment should be adopted to ensure that the patients
have the prerequisites for receiving treatment in a broad array of di-
mensions. By this, our findings could shed light on the recovery process
for this group of patients. It highlights the necessity of an ongoing diag-
nostic approach as the clinical picture at the admission of treatment
could be dramatically improved for patients suffering for polysubstance
use disorder. This knowledge could provide hope for patients, as well as
therapist, simply by highlighting the importance of time and continued
abstinence. This might subsequently reduce dropout numbers and im-
prove the recovery process for these patients. Future research should
consider the timing and sequence of interventions in SUD treatment.
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